[Pe-09] English Poster Session 09 Neuroimmunology 02

[Pe-09-7] Eculizumab efficacy and safety in NMOSD patients treated with prior rituximab: findings from PREVENT

^○Kazuo Fujihara^1,2, Michael Levy³, Achim Berthele⁴, Ho Jin Kim⁵, Ichiro Nakashima⁶, Celia Oreja-guevara⁷, Jacqueline Palace⁸, Sean J Pittock⁹, Murat Terzi¹⁰, Dean M Wingerchuk⁹ (1.Southern TOHOKU Research Institute for Neuroscience (STRINS), Japan, 2.Fukushima Medical University, Japan, 3.Massachusetts General Hospital and Harvard Medical School, 4.Technical University of Munich, 5.Research Institute and Hospital, Goyang, 6.Tohoku Medical and Pharmaceutical University, 7.Hospital Universitario Clinico San Carlos, 8.John Radcliffe Hospita, 9.Mayo Clinic, 10.Ondokuz Mayis University)

Kazuo Fujihara, M.D.is Professor, Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine, and Director, Multiple Sclerosis & Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience (STRINS), Koriyama, Japan. He is currently serving as President (2018~) of Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), and President (2019~) of Japanese Society for Neuroimmunology (JSNI).